CHMP March 2015: BI-Lilly closes in on diabetes fray
This article was originally published in Scrip
Executive Summary
On 27 March 2015, the European Medicines Agency's advisors gave the BI-Lilly Diabetes Alliance a little push forward, voting in favor of Synjardy, its fixed dose combination (FDC) of SGLT2 inhibitor Jardiance (empagliflozin) with metformin for treating Type 2 diabetes mellitus. But while the decision in Europe is important, Europe is not a big market for FDC products in diabetes. BI-Lilly's real battle in the SGLT2 market will be fought around the long-term safety data of SGLT2 compounds and on their efficacy when combined in fixed doses with gliptins.